Egeberg A, et al. - A comparative scrutiny was carried out of the safety, efficacy, and drug survival, with regard to how long patients stayed on therapy for 5 biologics: Adalimumab, etanercept, infliximab, secukinumab, and ustekinumab in the treatment of moderate-to-severe plaque psoriasis. Additionally, experts compared the originator versions of etanercept and infliximab to their biosimilar versions. It was determined that ustekinumab and secukinumab were only been available for 8 and 2 years, respectively. During this period, 30.3% and 28.8% of patients discontinued these therapies, respectively. Data unveiled highest response to therapy for ustekinumab, followed by adalimumab.

Methods

• Data analysis was performed from 3,495 treatment series in 2,161 patients.

Results

• In contrast with other drugs, substantially higher drug survival was found for ustekinumab.
• Secukinumab illustrated shortest survival and thereby highest risk of discontinuation of therapy.
• The occurrence of adverse events were noted most frequently with secukinumab.
• No notable effect was revealed on the drug survival while switching from an originator to a biosimilar version.
• This appeared to occur more rapidly for those treated with secukinumab as their first-ever biologic, among individuals that obtained complete skin clearance.
• The occurrence of therapy discontinuation was reported in 45.7% (adalimumab), 64.9% (etanercept), and 54.4% (infliximab) of patients over a 10-year period.